Carver Kyle has filed 5 insider transactions across 1 company since November 2025.
Most recent transaction: a grant/award of 98946 shares of Evommune, Inc. ($EVMN) on April 16, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 16, 2026 | Evommune, Inc. | $EVMN | Carver Kyle | Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 98946 | $0.00 | 98,946.0000 | 31,524,093 | 9999.99% | 0.31% |
| Dec. 9, 2025 | Evommune, Inc. | $EVMN | Carver Kyle | Chief Financial Officer | F | Common Stock | 13290 | $17.84 | 62,510.0000 | 0 | 17.53% | 0.00% |
| Nov. 7, 2025 | Evommune, Inc. | $EVMN | Carver Kyle | Chief Financial Officer | C | Common Stock | 3175 | $0.00 | 75,800.0000 | 0 | 4.37% | 0.00% |
| Nov. 7, 2025 | Evommune, Inc. | $EVMN | Carver Kyle | Chief Financial Officer | C | Series B Preferred Stock | 25000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Nov. 5, 2025 | Evommune, Inc. | $EVMN | Carver Kyle | Chief Financial Officer | A | Employee Stock Option (Right to Buy) | 279408 | $0.00 | 279,408.0000 | 0 | 9999.99% | 0.00% |